# Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent

> **NCT03806699** · PHASE1 · UNKNOWN · sponsor: **Quratis Inc.** · enrollment: 36 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** ID93+GLA-SE

## Key facts

- **NCT ID:** NCT03806699
- **Lead sponsor:** Quratis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-02
- **Primary completion:** 2020-09
- **Final completion:** 2020-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806699, "Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03806699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*